Skip to main content
. 2021 Feb 26;2(4):619–628. doi: 10.34067/KID.0007322020

Table 1.

Baseline characteristics by AKI status in the study cohorts

Clinical Variable Coronavirus Disease 2019 Influenza
No AKI (n=219) AKI (n=106) P value No AKI (n=290) AKI (n=143) P value
Age (yr) 62 (47–75) 67 (57–81) 0.01 72 (59–85) 73 (60–84) 0.5
Female 111 (51) 47 (44) 0.3 180 (62) 81 (57) 0.3
Race 0.006 0.02
 Black 99 (45) 68 (64) 58 (20) 46 (32)
 Non-Hispanic white 86 (39) 28 (26) 221 (76) 92 (64)
 Hispanic/other 34 (16) 10 (9) 11 (4) 5 (4)
Primary payor <0.0001 0.09
 Medicare 110 (50) 76 (72) 215 (74) 116 (81)
 Medicaid 38 (17) 13 (12) 32 (11) 17 (12)
 Managed care 71 (32) 15 (14) 41 (14) 9 (6)
 Other 0 2 (2) 2 (0.7) 1 (0.7)
BMI, kg/m2 31.2 (26.3–36.1) 28.6 (24.4–37.1) 0.99 27.9 (23.9–33.8) 29.6 (24.7–34.9) 0.2
Residence on admit 0.03 0.07
 Home 177 (81) 74 (70) 261 (90) 120 (84)
 Other 42 (19) 32 (30) 29 (10) 23 (16)
Diabetes mellitus 71 (37) 56 (58) 0.0005 87 (33) 56 (42) 0.07
Hypertension 96 (50) 60 (63) 0.04 165 (62) 93 (69) 0.1
Heart failure 34 (18) 35 (37) 0.0004 60 (22) 52 (39) 0.0005
CAD 31 (16) 26 (27) 0.03 76 (28) 41 (31) 0.6
PVD 14 (7) 8 (8) 0.7 30 (11) 15 (11) 1
COPD 33 (17) 18 (19) 0.7 103 (38) 48 (36) 0.6
Asthma 33 (17) 22 (23) 0.2 86 (32) 41 (31) 0.8
CKD 25 (13) 52 (54) <0.0001 44 (16) 76 (56) <0.0001
Comorbidity count 0.0001 0.009
 0–1 98 (51) 30 (31) 98 (37) 33 (24)
 2–3 65 (34) 31 (32) 91 (34) 43 (32)
 4+ 30 (16) 35 (37) 79 (30) 59 (44)
RAAS medications 74 (34) 53 (50) 0.005 121 (42) 71 (50) 0.1
Immunosuppression 24 (11) 14 (13) 0.6 131 (45) 66 (46) 0.8
Neutrophil/lymphocyte ratio 4.2 (2.6–8.4) 4.5 (2.9–8.1) 0.2 7.2 (4.0–13.6) 6.8 (4.0–11.2) 0.9
Baseline sCr (mg/dl) 0.8 (0.7–1.0) 1.0 (0.9–1.2) <0.0001 0.8 (0.7–1.0) 1.0 (0.8–1.2) <0.0001

Data are presented as median (IQR) or number (%). BMI, body mass index; CAD, coronary artery disease; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; RAAS, renin angiotensin aldosterone system; sCr, serum creatinine.